It is widely reported that healthcare is a top antitrust enforcement priority in the U.S. The healthcare industry has undergone a transformation over the over the last twenty years and now comprises 17.7% of the U.S. gross domestic product and over $3.795 trillion of the U.S. government budget. Mega-deals among national payors and household names have grabbed headlines and been targets of enforcement by the U.S. Department of Justice, Antitrust Division (the “DOJ”) and Federal Trade Commission (“FTC”) (collectively, “the Agencies”).
Continue Reading Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs
About
Michael McKinnon is a partner in the Corporate Practice Group in the firm's Orange County office and leader of the firm's Healthcare Private Equity Team.
Latest Post
More Posts
Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs
Putting the Brakes on Healthcare M&A and Provider/Payor Contracting: AB 2080 Poised to Dramatically Impact Healthcare Transactions in California
Trends in Digital Health Funding and Transactions: A Tremendous Year So Far
Private Equity and Healthcare – MedPAC’s Desire for More Transparency in Provider Ownership
CMS “Hospitals Without Walls” Waiver: Looking To ASCs to Provide Relief
SEC Guidance on COVID-19 Disclosures for Healthcare Providers
2019 Moss Adams Health Care Conference – Vision 2020: The Future of Health Care
The Overpayment Rule and the Implied False Claims Theory: “What You Don’t Know Can Still Hurt You”
About
Michael McKinnon is a partner in the Corporate Practice Group in the firm's Orange County office and leader of the firm's Healthcare Private Equity Team.